These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19765886)

  • 41. [A clinical study of recurrence and progression of grade 3 superficial bladder tumor].
    Ikegami S; Tsuji A; Suzuki S; Sumitomo M; Kimura F; Asano T; Nakajima F; Hayakawa M
    Hinyokika Kiyo; 1999 May; 45(5):325-9. PubMed ID: 10410314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Difficulties of the new classification system for bladder cancer].
    Ghorra C; Nemr E; Vieillefond A
    J Med Liban; 2002; 50(4):180-3. PubMed ID: 15298479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Urinary bladder tumors. Report of the Danish Bladder-cancer Committee 1993].
    Ugeskr Laeger; 1997; 159 Suppl 1():1-14. PubMed ID: 9273765
    [No Abstract]   [Full Text] [Related]  

  • 45. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up.
    Mariappan P; Fineron P; O'Donnell M; Gailer RM; Watson DJ; Smith G; Grigor KM
    World J Urol; 2021 Feb; 39(2):425-431. PubMed ID: 32266509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.
    Otto W; Denzinger S; Fritsche HM; Burger M; Wieland WF; Hofstädter F; Hartmann A; Bertz S
    BJU Int; 2011 Feb; 107(3):404-8. PubMed ID: 20707791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of 2004 ISUP/WHO classification on bladder cancer grading.
    Lokeshwar SD; Ruiz-Cordero R; Hupe MC; Jorda M; Soloway MS
    World J Urol; 2015 Dec; 33(12):1929-36. PubMed ID: 25833661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder.
    Mangrud OM; Waalen R; Gudlaugsson E; Dalen I; Tasdemir I; Janssen EA; Baak JP
    PLoS One; 2014; 9(1):e83192. PubMed ID: 24409280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contemporary Grading and Staging of Urothelial Neoplasms of the Urinary Bladder: New Concepts and Approaches to Challenging Scenarios.
    Gallan AJ; Choy B; Paner GP
    Surg Pathol Clin; 2018 Dec; 11(4):775-795. PubMed ID: 30447841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bladder. Risk and prognostic factors--a pathologist's perspective.
    Reuter VE
    Urol Clin North Am; 1999 Aug; 26(3):481-92. PubMed ID: 10494286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A dynamic model for the risk of bladder cancer progression.
    Porta N; Calle ML; Malats N; Gómez G
    Stat Med; 2012 Feb; 31(3):287-300. PubMed ID: 22161505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading.
    Liedberg F; Lauss M; Patschan O; Aine M; Chebil G; Cwikiel M; Engilbertsson H; Gudjonsson S; Kollberg P; Sjödahl G; Månsson W; Lindgren D; Höglund M;
    Eur Urol; 2012 Oct; 62(4):620-3. PubMed ID: 22698575
    [No Abstract]   [Full Text] [Related]  

  • 55. Neural network-based segmentation and classification system for automated grading of histologic sections of bladder carcinoma.
    Spyridonos P; Cavouras D; Ravazoula P; Nikiforidis G
    Anal Quant Cytol Histol; 2002 Dec; 24(6):317-24. PubMed ID: 12508689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors: reply.
    Cheng L; Bostwick DG
    Cancer; 2000 Apr; 88(7):1513-6. PubMed ID: 10738206
    [No Abstract]   [Full Text] [Related]  

  • 57. Morphometric grading of bladder tumors in comparison with histologic grading by pathologists.
    Ooms EC; Kurver PH; Veldhuizen RW; Alons CL; Boon ME
    Hum Pathol; 1983 Feb; 14(2):144-50. PubMed ID: 6832759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bladder tumor histoseminar - Introduction. Bladder tumours diagnosis facing new treatments and new molecular classifications].
    Allory Y
    Ann Pathol; 2016 Dec; 36(6):371-372. PubMed ID: 27838083
    [No Abstract]   [Full Text] [Related]  

  • 59. Split-dose radiotherapy for bladder carcinoma. 94 cases treated from 1960 through 1966.
    Scanlon PW; Furlow WL
    Radiology; 1970 Oct; 97(1):141-8. PubMed ID: 5459347
    [No Abstract]   [Full Text] [Related]  

  • 60. Reproducibility and reliability of tumor grading in urological neoplasms.
    Engers R
    World J Urol; 2007 Dec; 25(6):595-605. PubMed ID: 17828603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.